You have read all your free articles, to continue reading subscribe to read the rest of this content.
The two companies are now supplying Ximluci (ranibizumab biosimilar) in England via a National Health Service (NHS) England Framework Agreement. The partners announced in January 2023 that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) had granted a marketing authorization Already a subscriber Login You have read all your…
BerGenBio announces the award of a NOK 24 million (USD 2.85m) grant from Innovasjon Norge to support the clinical development of BGB324 in combination with Merck & Co.’s KEYTRUDA (pembrolizumab) in patients with advanced lung cancer. BerGenBio will sponsor a Phase II study multi-centre studAlready a subscriber Login You have…
Swedish Orphan Biovitrum (Sobi) announces that the company has entered into a 3-year agreement with Valeant Pharmaceuticals Ireland for the distribution of Ammonul (sodium phenyl acetate and sodium benzoate) injection in Europe, the Middle East and North Africa. The new agreement replaces the curAlready a subscriber Login You have read…
Genmab has entered into a strategic collaboration agreement with Tempus, a privately-owned technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The multi-year collaboration will combine Tempus’ sequencing capabilities and plAlready a subscriber Login You have read all your free articles, to continue reading subscribe…
